SUPERNUS PHARMACEUTICALS, INC. and WILMINGTON TRUST, NATIONAL ASSOCIATION as TrusteeIndenture • March 20th, 2018 • Supernus Pharmaceuticals Inc • Pharmaceutical preparations • New York
INDENTURE, dated as of March 19, 2018, between Supernus Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and Wilmington Trust, National Association, as trustee (the “Trustee”).
Supernus Pharmaceuticals, Inc.Purchase Agreement • March 20th, 2018 • Supernus Pharmaceuticals Inc • Pharmaceutical preparations • New York
c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, NY 10036 Attn: Robert Stewart, Assistant General Counsel Telephone: 646-855-0711 Facsimile: 646-822-5618 March 14, 2018 To: Supernus Pharmaceuticals, Inc. Rockville,...Base Issuer Warrant Transaction • March 20th, 2018 • Supernus Pharmaceuticals Inc • Pharmaceutical preparations • New York
The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”) between Bank of America, N.A. (“Dealer”) and Supernus Pharmaceuticals, Inc. (“Issuer”). This communication constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below.
Bank of America, N.A. c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, NY 10036Additional Convertible Bond Hedge Transaction • March 20th, 2018 • Supernus Pharmaceuticals Inc • Pharmaceutical preparations • New York
The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”) between Bank of America, N.A. (“Dealer”) and Supernus Pharmaceuticals, Inc. (“Counterparty”). This communication constitutes a “Confirmation” as referred to in the ISDA 2002 Master Agreement specified below.
Bank of America, N.A. c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, NY 10036Additional Issuer Warrant Transaction • March 20th, 2018 • Supernus Pharmaceuticals Inc • Pharmaceutical preparations • New York
The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”) between Bank of America, N.A. (“Dealer”) and Supernus Pharmaceuticals, Inc. (“Issuer”). This communication constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below.
Bank of America, N.A. c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, NY 10036Base Convertible Bond Hedge Transaction • March 20th, 2018 • Supernus Pharmaceuticals Inc • Pharmaceutical preparations • New York
The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”) between Bank of America, N.A. (“Dealer”) and Supernus Pharmaceuticals, Inc. (“Counterparty”). This communication constitutes a “Confirmation” as referred to in the ISDA 2002 Master Agreement specified below.
